Clinical validation of an autoantibody test for lung cancer

Annals of Oncology

Volumn 22, Issue 2, 2011, Pages 383-389

  Boyle, P ^a   Chapman, C J ^b   Holdenrieder, S ^c   Murray, A ^d   Robertson, C ^e   Wood, W C ^f   Maddison, P ^g   Healey, G ^d   Fairley, G H ^d   Barnes, A C ^d   Robertson, J F R ^b  

^a INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^e UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Autoantibodies; Clinical validation; Lung cancer; Newly diagnosed patients

Indexed keywords

AUTOANTIBODY; LIPOCORTIN 1; NY ESO 1 ANTIGEN; PROTEIN CAGE; PROTEIN GBU4; PROTEIN GBU5; PROTEIN P53; TRANSCRIPTION FACTOR SOX2; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; AREA UNDER THE CURVE; ARTICLE; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; LARGE CELL LYMPHOMA; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SMALL CELL CARCINOMA; SMOKING; VALIDATION STUDY;

EID: 79251554099     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq361     Document Type: Article

References (53)

1. Boyle P, Levin B (eds). World Cancer Report 2008. Lyon, France: IARC 2008.
2. Horner MJ, Ries LAG, Krapcho M et al. (eds). SEER Cancer Statistics Review, 1975-2006. Bethesda, MD: National Cancer Institute 2009: http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER data submission, posted to the SEER website (February 2010, date last accessed).
3. Sone S, Takashima S, Li F et al. Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet 1998; 351: 1242-1245.
4. Henschke CI, McCauley DI, Yankelevitz DF, Altorki NK. Early lung cancer action project: overall design and findings from baseline screening. Lancet 1999; 354: 99-105.
5. Swensen SJ, Jett JR, Hartman TE et al. CT screening for lung cancer: five-year prospective experience. Radiology 2005; 235: 259-265.
6. Sobue T, Moriyama N, Kaneko M et al. Screening for lung cancer with low-dose helical computed tomography: anti-lung cancer association project. J Clin Oncol 2002; 20: 911-920.
7. Henschke CI, Naidich DP, Yankelevitz DF et al. Early lung cancer action project: initial findings on repeat scanning. Cancer 2001; 92: 153-159.
8. Diederich S, Wormanns D, Semik M et al. Screening for early lung cancer with low-dose spiral CT: prevalence in 817 asymptomatic smokers. Radiology 2002; 222: 773-781.
9. Nawa T, Nakagawa T, Suzushi S et al. Lung cancer screening using low-dose spiral CT: results of baseline and 1-year follow-up studies. Chest 2002; 122: 15-20.
10. Gohagan J, Marcus P, Fagerstrom R et al. Writing Committee, Lung Screening Study Research Group. Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph: the Lung Screening Study of the National Cancer Institute. Chest 2004; 126: 114-121.
11. McWilliams A, Mayo J, MacDonald S et al. Lung cancer screening: a different paradigm. Am J Respir Crit Care Med 2003; 168: 1167-1173.
12. Kaneko M, Eguchi K, Ohmatsu H et al. Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology 1996; 201: 798-802.
13. Berrington de Gonzalez A, Mahesh M, Kim K et al. Projected cancer risks from computed tomography scans performed in the United States in 2007. Arch Intern Med 2009; 169: 2071-2077.
14. Sone S, Li F, Yang ZG et al. Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner. Br J Cancer 2001; 84: 25-32.
15. McWilliams AM, MacAulay C, Gazdar AF, Lam S. Innovative molecular and imaging approaches for the detection of lung cancer and its precursor lesions. Oncogene 2002; 21: 6949-6959.
16. Tan EM. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest 2001; 108: 1411-1415.
17. Houghton AN. Cancer antigens: immune recognition of self and altered self. J Exp Med 1994; 180: 1-4.
18. Brichory FM, Misek DE, Yim AM et al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A 2001; 98: 9824-9829.
19. Zhang J, Casiano CA, Peng X et al. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Bio and Prev 2003; 12: 136-143.
20. Nesterova M, Johnson N, Cheadle C et al. Autoantibody biomarker opens a new gateway for cancer diagnosis. Biochimica et Biophysica Acta 2006; 1762: 398-403.
21. Robertson JFR, Chapman CJ, Cheung KL et al. Auto-antibodies in early breast cancer. J Clin Oncol 2005; 23: 549.
22. Zhong L, Coe SP, Stromberg AJ et al. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thor Oncol 2006; 1: 513-519.
23. Chapman C, Murray A, Chakrabarti J et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 2007; 18: 868-873.
24. Chapman CJ, Murray A, McElveen JE et al. Autoantibodies in lung cancer-possibilities for early detection and subsequent cure. Thorax 2008; 63: 228-233.
25. Crawford LV, Pim DC, Bulbrook RD. The detection of antibodies against the cellular protein p53 in sera from patients with breast-cancer. Int J Cancer 1982; 30: 403-408.
26. Li Y, Brandt-Rauf PW, Carney WP et al. Circulating anti-p53 antibodies in lung cancer and relationship to histology and smoking. Biomarkers 1999; 4: 381-390.
27. Trivers GE, DeBenedetti VM, Cawley HL et al. Anti p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res 1996; 2: 1767-1775.
28. Gnjatic S, Nishikawa H, Jungbluth AA et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 2006; 95: 1-30.
29. Cho B, Lim Y, Lee DY et al. Identification and characterization of a novel cancer/testis antigen gene CAGE. Biochem Biophys Res Commun 2002; 292: 715-726.
30. Krause P, Tureci O, Micke P et al. SeroGRID: an improved method for the rapid selection of antigens with disease related immunogenicity. J Immunol Methods 2003; 283: 261-267.
31. Türeci O, Mack U, Luxemberger U et al. Humoral responses of lung cancer patients against tumor antigen NY-ESO-1. Cancer Lett 2006; 236: 64-71.
32. Vural B, Chen L-C, Saip P et al. Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters. Cancer 2005; 103: 2575-2583.
33. Maddison P, Thorpe A, Silcocks P et al. Autoimmunity to SOX2, clinical phenotype and survival in patients with small-cell lung cancer. Lung Cancer 2010 April 3 [Epub ahead of print].
34. Robertson JFR, Barnes T, Murray A, Chapman C. Improved Immunoassay Methods WO2006/126/008. Nottingham, GB: Oncimmune Ltd 2006.
35. Murray A, Chapman CJ, Healey G et al. Technical validation of an autoantibody test for lung cancer. Ann Oncol 2010; 21: 1687-1693.
36. Robertson JFR, Murray A, Chapman C, Barnes A. Calibrator for Immunoassays WO2009/081165. Nottingham, GB: Oncimmune Ltd 2007.
37. Motulsky H, Christopoulos A. Fitting Models to Biological Data Using Linear and Nonlinear Regression (Chapter 41), Madison Avenue, NY: Oxford University Press 2004.
38. Geyer C. Estimation and optimization of functions. In Gilks WR, Richardson ST, Speigelhalter DJ (eds), Markov Chain Monte Carlo In Practice. London: Chapman and Hall 1999; 241-258.
39. Spitz MR, Hong WK, Amos CI et al. A risk model for prediction of lung cancer. J Natl Cancer Inst 2007; 99: 715-726.
40. Sangrajrang S, Sornprom A, Chernrungroj G, Soussi T. Serum p53 antibodies in patients with lung cancer: correlation with clinicopathologic features and smoking. Lung Cancer 2003; 39: 297-301.
41. Li Y, Karjalainen A, Koskinen H et al. p53 Autoantibodies predict subsequent development of cancer. Int J Cancer 2005; 114: 157-160.
42. Cho B, Lee H, Jeong S et al. Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric cancer. Biochem Biophys Res Commun 2002; 307: 52-63.
43. Qiu J, Choi G, Li L et al. Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol 2008; 26: 5060-5066.
44. Gure AO, Stockert E, Scanlan M et al. Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer. Proc Natl Acad Sci U S A 2000; 97: 4198-4203.
45. Pereira-Faca SR, Kuick R, Puravs E et al. Identification of 14-3-3u as an antigen that induces a humoral response in lung cancer. Cancer Res 2007; 67: 12000-12006.
46. Robertson JFR, Pearson D, Price MR et al. Assessment of four monoclonal antibodies as serum markers in breast cancer. Eur J Cancer 1990; 26: 1127-1132.
47. Robertson JFR, Pearson D, Price MR et al. Prospective assessment of the role of five serum markers in breast cancer. Cancer Immunol Immunother 1991; 33: 403-410.
48. Laurence DJR, Stevens U, Bettelheim R et al. Role of plasma carcinoembryonic antigen in the diagnosis of gastro-intestinal, mammary and bronchial carcinoma. Br Med J 1972; 3: 605-609.
49. Thomas MW, Robertson JFR, Price MR, Hardcastle JD. Failure of CA 19-9 to detect asymptomatic colorectal carcinoma. Br J Cancer 1991; 63: 975-976.
50. Robertson JFR, Graves CRL, Price MR. Tumour Markers US 7,402,403, B1. Nottingham, GB: Oncimmune Ltd 1999.
51. Rohayem J, Diestelkoetter P, Weigle B et al. Antibody response to the tumor-associated inhibitor of apoptosis protein surviving in cancer patients. Cancer Res 2000; 60: 1815-1817.
52. Suzuki H, Graziano DF, McKolanis J, Finn OJ. T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin Cancer Res 2005; 11: 1521-1526.
53. Pisano ED, Gatsonis C, Hendrick E et al. Diagnostic performance of digital versus film mammography for breast cancer screening. N Engl J Med 2005; 353: 1773-1783.